Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...

CHAF1B, a histone chaperone component of the chromatin assembly factor-1 complex, is overexpressed in multiple cancers and linked to tumor progression, but its role in lung squamous-cell carcinoma ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...

Safety and Efficacy of Antiangiogenesis Agents in Patients With Squamous Cell Carcinoma of the Lung: Time to Revise Outdated Constraints. 1 , e2400089 (2024). DOI: 10.1200/OA-24-00089 ...

Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs ...

Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients. PR Newswire. IRVING, Texas, May 12, 2025.

SKYSCRAPER-06 is a global Phase II/III, randomized, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq ® (atezolizumab) and chemotherapy as an initial (first-line ...

In a phase 3, randomized trial, we enrolled patients with local or regional cutaneous squamous-cell carcinoma, after surgical resection and postoperative radiotherapy, at high risk for recurrence ...